ELDN Insider Trading (Eledon Pharmaceuticals)
Insider Ownership Percentage: 13.80%
Insider Buying (Last 12 Months): $33,800.00
Insider Selling (Last 12 Months): $0.00
Eledon Pharmaceuticals Share Price & Price History
Current Price: $2.45
Price Change: ▲ Price Increase of +0.01 (0.41%)
As of 07/1/2022 04:59 PM ET
The Safest Option in Trades!
From Tradewins | Ad
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.
And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!
Eledon Pharmaceuticals Insider Trading History
Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
---|
12/20/2021 | David-Alexandre C. Gros | CEO | Buy | 2,000 | $4.48 | $8,960.00 | | |
8/17/2021 | David-Alexandre C. Gros | CEO | Buy | 4,000 | $6.21 | $24,840.00 | 7,000 | |
6/9/2021 | David-Alexandre C. Gros | CEO | Buy | 3,000 | $8.01 | $24,030.00 | 3,000 | |
A One Stop Shop for Everything Futures Trading
From RJO Futures | Ad
Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!
Download your FREE Technical Analysis Trading Guide Today.
Eledon Pharmaceuticals Institutional Trading History
Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
---|
5/16/2022 | Woodline Partners LP | 673,138 | $2.65M | 0.0% | -13.9% | 4.893% |  |
5/16/2022 | State Street Corp | 44,692 | $0.18M | 0.0% | +10.5% | 0.325% |  |
5/13/2022 | Renaissance Technologies LLC | 18,473 | $73K | 0.0% | +35.1% | 0.134% |  |
5/13/2022 | Vanguard Group Inc. | 679,243 | $2.68M | 0.0% | +1.4% | 4.936% |  |
5/9/2022 | CM Management LLC | 225,000 | $0.89M | 0.7% | +95.7% | 1.636% |  |
4/25/2022 | Bailard Inc. | 27,600 | $0.11M | 0.0% | N/A | 0.193% |  |
2/14/2022 | Point72 Asset Management L.P. | 431,435 | $1.90M | 0.0% | +105.9% | 3.016% |  |
2/11/2022 | Ensign Peak Advisors Inc | 77,100 | $0.34M | 0.0% | +966.7% | 0.539% |  |
2/7/2022 | Ameritas Advisory Services LLC | 24,219 | $0.11M | 0.0% | N/A | 0.169% |  |
2/2/2022 | CM Management LLC | 115,000 | $0.51M | 0.4% | +53.3% | 0.804% |  |
11/16/2021 | Two Sigma Advisers LP | 115,900 | $0.72M | 0.0% | +48.0% | 0.810% |  |
11/16/2021 | Two Sigma Investments LP | 115,324 | $0.71M | 0.0% | +100.5% | 0.806% |  |
11/16/2021 | BVF Inc. IL | 1,363,435 | $8.43M | 0.3% | +22.5% | 9.530% |  |
11/15/2021 | Point72 Asset Management L.P. | 209,490 | $1.30M | 0.0% | +11.0% | 1.464% |  |
11/15/2021 | Eversept Partners LP | 114,008 | $0.71M | 0.1% | N/A | 0.797% |  |
11/15/2021 | Ensign Peak Advisors Inc | 7,228 | $45K | 0.0% | -80.0% | 0.051% |  |
11/10/2021 | Mercer Global Advisors Inc. ADV | 16,726 | $0.10M | 0.0% | N/A | 0.117% |  |
8/18/2021 | Ikarian Capital LLC | 350,000 | $2.77M | 0.2% | +40.0% | 2.446% |  |
8/17/2021 | Woodline Partners LP | 857,445 | $6.78M | 0.1% | -3.8% | 5.993% |  |
8/17/2021 | Boothbay Fund Management LLC | 40,052 | $0.32M | 0.0% | +39.6% | 0.280% |  |
8/16/2021 | Point72 Asset Management L.P. | 188,690 | $1.49M | 0.0% | +51.0% | 1.319% |  |
8/16/2021 | Morgan Stanley | 851,004 | $6.73M | 0.0% | +7,235.6% | 5.948% |  |
8/16/2021 | State Street Corp | 32,935 | $0.26M | 0.0% | N/A | 0.230% |  |
8/13/2021 | Renaissance Technologies LLC | 21,107 | $0.17M | 0.0% | -22.0% | 0.148% |  |
8/13/2021 | Northern Trust Corp | 32,116 | $0.25M | 0.0% | +106.8% | 0.224% |  |
8/13/2021 | Geode Capital Management LLC | 124,614 | $0.99M | 0.0% | +25.7% | 0.871% |  |
8/13/2021 | Vanguard Group Inc. | 209,750 | $1.66M | 0.0% | -8.8% | 1.466% |  |
5/19/2021 | Logos Global Management LP | 224,071 | $2.40M | 0.2% | N/A | 1.566% |  |
5/18/2021 | BVF Inc. IL | 1,113,435 | $11.91M | 0.4% | N/A | 7.782% |  |
5/18/2021 | Millennium Management LLC | 14,588 | $0.16M | 0.0% | N/A | 0.102% |  |
5/18/2021 | Point72 Asset Management L.P. | 125,000 | $1.34M | 0.0% | N/A | 0.874% |  |
5/18/2021 | Cormorant Asset Management LP | 1,415,500 | $15.15M | 0.3% | N/A | 9.894% |  |
5/18/2021 | Citadel Advisors LLC | 25,062 | $0.27M | 0.0% | N/A | 0.175% |  |
5/17/2021 | Woodline Partners LP | 891,055 | $9.53M | 0.2% | N/A | 6.228% |  |
5/17/2021 | EcoR1 Capital LLC | 1,115,721 | $11.94M | 0.5% | N/A | 7.798% |  |
5/17/2021 | Janus Henderson Group PLC | 213,899 | $2.25M | 0.0% | N/A | 1.495% |  |
5/17/2021 | Ikarian Capital LLC | 250,000 | $2.68M | 0.1% | N/A | 1.747% |  |
5/13/2021 | Renaissance Technologies LLC | 27,051 | $0.29M | 0.0% | N/A | 0.189% |  |
5/12/2021 | Northern Trust Corp | 15,528 | $0.17M | 0.0% | N/A | 0.109% |  |
5/12/2021 | Geode Capital Management LLC | 99,123 | $1.06M | 0.0% | N/A | 0.693% |  |
5/12/2021 | CM Management LLC | 75,000 | $0.80M | 0.6% | N/A | 0.524% |  |
5/7/2021 | BlackRock Inc. | 12,282 | $0.13M | 0.0% | N/A | 0.086% |  |
4/21/2021 | Ingalls & Snyder LLC | 51,149 | $0.55M | 0.0% | N/A | 0.358% |  |
Data available starting January 2016
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Read More on Eledon Pharmaceuticals
Volume
1,620 shs
Average Volume
68,824 shs
Market Capitalization
$33.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.98
Who are the company insiders with the largest holdings of Eledon Pharmaceuticals?